jRCT2080222084未知1 期
Phase I study of YHI-1003 monotherapy in patients with relapsed or refractory neuroblastoma
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, Multicenter Trial
入排标准
- 年龄范围
- 2age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1)Patients were previously diagnosed with neuroblastoma
- •(2)Patients must have relapsed or refracted against the standard therary
排除标准
- •(1)Patients were previously treated with Perifosine.
结局指标
主要结局
-
safety CTCAE v.4.0
次要结局
未报告次要终点
研究者
相似试验
未知
2 期
Phase II trial of YHI-1003advanced or relapsed gynecologic cancer (ovarian, endometric or cervical cancer)jRCT2080222238Yakult Honsha Co., Ltd.96
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
未知
1 期
Phase I Trial of YHI-1501Healthy adult malejRCT2080223241Yakult Honsha Co., Ltd.68
未知
2 期
Phase II trial of YHI-1003advanced or relapsed gynecologic cancer (ovarian, endometric or cervical cancer)JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18